Lenalidomide/rituximab

Lenalidomide/rituximab Reactions 1704, p221 - 2 Jun 2018 Hypertension: case report A woman in her 50s [exact age not stated] developed hypertension during treatment with lenalidomide and rituximab [routes not stated; not all dosages stated] for recurrent marginal zone lymphoma (MZL). The woman, who had MZL, started receiving standard R- EPOCH chemotherapy, which included rituximab, etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin [hydroxydaunorubicin]. After receiving six cycles, she achieved a complete remission status. She remained in remission for eight months, after which she presented with a symptomatic relapse. Thereafter, she was enrolled in a clinical trial and started receiving treatment with lenalidomide 20mg and rituximab. She tolerated the first two cycles and all the disease related symptoms resolved. However, she experienced worsening hypertension. The woman’s lenalidomide therapy dose was reduced to 15mg starting from the third cycle. Five months after the enrolment, she was pulled out from the study following a hypertensive emergency episode [outcome not stated]. At that time she was in complete remission, which continued for the following two years despite not receiving any additional therapy. Author comment: "She was enrolled in a clinical trial assessing the role of different maintenance regimens after induction with lenalidomide and rituximab. The patient tolerated the first two cycles well with resolution of all disease related symptoms, however she developed worsening hypertension". Ibrahimi S, et al. Sustained response to lenalidomide for early relapsed marginal zone lymphoma. Blood Cells, Molecules and Diseases 71: 53-54, Jul 2018. Available from: URL: http://doi.org/10.1016/j.bcmd.2018.02.004 - USA 803324050 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Lenalidomide/rituximab

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/lenalidomide-rituximab-KG8F184R1J
Publisher
Springer International Publishing
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46864-2
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p221 - 2 Jun 2018 Hypertension: case report A woman in her 50s [exact age not stated] developed hypertension during treatment with lenalidomide and rituximab [routes not stated; not all dosages stated] for recurrent marginal zone lymphoma (MZL). The woman, who had MZL, started receiving standard R- EPOCH chemotherapy, which included rituximab, etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin [hydroxydaunorubicin]. After receiving six cycles, she achieved a complete remission status. She remained in remission for eight months, after which she presented with a symptomatic relapse. Thereafter, she was enrolled in a clinical trial and started receiving treatment with lenalidomide 20mg and rituximab. She tolerated the first two cycles and all the disease related symptoms resolved. However, she experienced worsening hypertension. The woman’s lenalidomide therapy dose was reduced to 15mg starting from the third cycle. Five months after the enrolment, she was pulled out from the study following a hypertensive emergency episode [outcome not stated]. At that time she was in complete remission, which continued for the following two years despite not receiving any additional therapy. Author comment: "She was enrolled in a clinical trial assessing the role of different maintenance regimens after induction with lenalidomide and rituximab. The patient tolerated the first two cycles well with resolution of all disease related symptoms, however she developed worsening hypertension". Ibrahimi S, et al. Sustained response to lenalidomide for early relapsed marginal zone lymphoma. Blood Cells, Molecules and Diseases 71: 53-54, Jul 2018. Available from: URL: http://doi.org/10.1016/j.bcmd.2018.02.004 - USA 803324050 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off